A Phase II Study of SB-715992 (NSC 727990) in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Ispinesib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 05 Jan 2007 The expected completion date for this trial is now 1 Jun 2007.
- 24 Aug 2006 Status change